[Skip to Navigation]
Sign In
Views 260
Citations 0
Comment & Response
April 8, 2021

Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data—Reply

Author Affiliations
  • 1Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona
JAMA Oncol. 2021;7(6):941. doi:10.1001/jamaoncol.2021.0534

In Reply We thank Xie et al for their interest in our recent systematic review and meta-analysis.1 We used progression-free survival (PFS) as reported in the included trials. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to assess the progression event in PFS in all refractory hepatocellular carcinoma trials except the RESORCE trial,2 in which modified RECIST was used. However, as reported by the trial,2 the PFS was comparable when using RECIST and modified RECIST. In addition, our primary end point of overall survival1 is not affected by assessment of response and is considered a more objective and gold standard end point in oncology.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×